Thoratec-HeartWare LVAD Deal Is Dead Following FTC Challenge
This article was originally published in The Gray Sheet
Executive Summary
Thoratec abandoned its planned $282 million acquisition of ventricular-assist-device-maker HeartWare July 31 after the deal was challenged by the Federal Trade Commission
You may also be interested in...
Heart Failure Devices: Raising Roadblocks To Readmission
A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.
Heart Failure Devices: Raising Roadblocks To Readmission
A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.
HeartMate Meets Its Match? HeartWare VAD Data Has Good Showing At AHA
Thoratec's days monopolizing the ventricular assist device market with its HeartMate VAD technology appear to be numbered. That's the consensus out of last week's American Heart Association annual meeting, where upstart HeartWare reported impressive results for its next-generation VAD in late-stage heart failure patients waiting for a transplant.